Literature DB >> 16584731

Downregulation of survivin expression enhances sensitivity of cultured uveal melanoma cells to cisplatin treatment.

Haochuan Li1, Jerry Y Niederkorn, Sudha Neelam, Hassan Alizadeh.   

Abstract

The purpose of this study is to evaluate the effect of a novel anti-apoptotic gene, survivin, on the resistance and susceptibility of human uveal melanoma cells to apoptosis induced by cisplatin. The sensitivity of human uveal melanoma cell lines to apoptosis induced by cisplatin was analyzed by caspase-3 assays. The expression of the anti-apoptotic protein, survivin, was examined by flow cytometry. Melanoma cells were transfected with either survivin cDNA or survivin anti-sense cDNA and examined for susceptibility to cisplatin-induced apoptosis. Six human uveal melanoma cell lines were incubated with or without cisplatin and cellular proliferation was determined by MTT assays. Significant growth inhibition was observed in 3 melanoma cell lines (OMM1, OCM3, and MEL 270). By contrast, 3 cell lines (OMM2.5, OMM2.3, and 92-1) were resistant to cisplatin-induced apoptosis. However, a positive association was observed between resistance to cisplatin-induced apoptosis and high expression of the anti-apoptotic protein, survivin. Up-regulation of survivin by gene transfer enhanced resistance to cisplatin-induced apoptosis, while transfection with survivin anti-sense rendered resistant melanoma cells susceptible to cisplatin. The combination of cisplatin and actinomycin D significantly decreased survivin expression and enhanced the cisplatin-induced apoptosis of uveal melanoma cells in vitro. These data indicate that resistance of some uveal melanoma cells to cisplatin-induced apoptosis is controlled by anti-apoptotic proteins, such as survivin, that are sensitive to actinomycin D treatment.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16584731     DOI: 10.1016/j.exer.2005.11.024

Source DB:  PubMed          Journal:  Exp Eye Res        ISSN: 0014-4835            Impact factor:   3.467


  9 in total

1.  siRNA directed against survivin enhances pancreatic cancer cell gemcitabine chemosensitivity.

Authors:  Wen-Song Liu; Hai-Jiao Yan; Ren-Yi Qin; Rui Tian; Min Wang; Jian-Xin Jiang; Ming Shen; Cheng-Jian Shi
Journal:  Dig Dis Sci       Date:  2008-07-02       Impact factor: 3.199

2.  High levels of Hdmx promote cell growth in a subset of uveal melanomas.

Authors:  Job de Lange; Amina Fas Teunisse; Matty Verlaan-de Vries; Kirsten Lodder; Suzanne Lam; Gregorius Pm Luyten; Federico Bernal; Martine J Jager; Aart G Jochemsen
Journal:  Am J Cancer Res       Date:  2012-08-20       Impact factor: 6.166

3.  Theranostic properties of a survivin-directed molecular beacon in human melanoma cells.

Authors:  Sara Carpi; Stefano Fogli; Ambra Giannetti; Barbara Adinolfi; Sara Tombelli; Eleonora Da Pozzo; Alessia Vanni; Enrica Martinotti; Claudia Martini; Maria Cristina Breschi; Mario Pellegrino; Paola Nieri; Francesco Baldini
Journal:  PLoS One       Date:  2014-12-11       Impact factor: 3.240

4.  On the discovery of a potential survivin inhibitor combining computational tools and cytotoxicity studies.

Authors:  Patricia A Quispe; Martin J Lavecchia; Ignacio E León
Journal:  Heliyon       Date:  2019-08-10

5.  Verification of EZH2 as a druggable target in metastatic uveal melanoma.

Authors:  Bei Jin; Ping Zhang; Hailin Zou; Huijing Ye; Yun Wang; Jing Zhang; Huasheng Yang; Jingxuan Pan
Journal:  Mol Cancer       Date:  2020-03-04       Impact factor: 27.401

Review 6.  Role of Natural Killer Cells in Uveal Melanoma.

Authors:  Asad Javed; Mohammed Milhem
Journal:  Cancers (Basel)       Date:  2020-12-09       Impact factor: 6.639

7.  Transcriptional inhibition by CDK7/9 inhibitor SNS-032 abrogates oncogene addiction and reduces liver metastasis in uveal melanoma.

Authors:  Jing Zhang; Shenglan Liu; Qianyun Ye; Jingxuan Pan
Journal:  Mol Cancer       Date:  2019-09-16       Impact factor: 27.401

8.  Salinomycin effectively eliminates cancer stem-like cells and obviates hepatic metastasis in uveal melanoma.

Authors:  Jingfeng Zhou; Shenglan Liu; Yun Wang; Wei Dai; Hailin Zou; Shubo Wang; Jing Zhang; Jingxuan Pan
Journal:  Mol Cancer       Date:  2019-11-13       Impact factor: 27.401

9.  Pan-cancer analysis identifies BIRC5 as a prognostic biomarker.

Authors:  Anna Fäldt Beding; Peter Larsson; Khalil Helou; Zakaria Einbeigi; Toshima Z Parris
Journal:  BMC Cancer       Date:  2022-03-25       Impact factor: 4.430

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.